Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 20/20 | 0.90 |
| ▸ | KAT6A | Q92794 | 20/20 | 0.90 |
| ▸ | KAT6B | Q8WYB5 | 13/20 | 0.90 |
| ▸ | KAT5 | Q92993 | 13/20 | 0.90 |
| ▸ | KAT8 | Q9H7Z6 | 13/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prifetrastat SCHEMBL29490368 | 1.00 | KAT7 (0.90) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26165855 | 0.95 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31472954 | 0.93 | KAT6A (0.88) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL27184209 | 0.93 | KAT7 (0.78) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30360863 | 0.93 | KAT7 (0.78) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL25561720 | 0.93 | KAT7 (0.80) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL29017507 | 0.92 | KAT7 (0.81) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22817465 | 0.91 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22817455 | 0.91 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30636971 | 0.91 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027087-A1 | DOSING REGIMENS COMPRISING A KAT6 INHIBITOR FOR THE TREATMENT OF CANCER | PFIZER (US) | 2026-01-29 | — | — | US | claimed |
| EP-4667055-A2 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | Pfizer Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4181920-B1 | KAT6 INHIBITOR AND COMBINATIONS FOR BREAST CANCER TREATMENT | PFIZER (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | claimed |
| CN-116113407-A | KAT6 inhibitor methods and combinations for cancer treatment | 辉瑞公司 | 2023-05-12 | — | — | CN | claimed |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2022-11-08 | — | — | US | claimed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| CN-114364672-A | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2022-04-15 | — | — | CN | claimed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | claimed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | claimed |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260027087-A1 | DOSING REGIMENS COMPRISING A KAT6 INHIBITOR FOR THE TREATMENT OF CANCER | PFIZER (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4667055-A2 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | Pfizer Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4181920-B1 | KAT6 INHIBITOR AND COMBINATIONS FOR BREAST CANCER TREATMENT | PFIZER (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | KAT7 1917/4885KAT6A 3783/4885KAT6B 2859/4885 |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | KAT7 1841/4885KAT6A 3700/4885KAT6B 2765/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | KAT7 3/4885KAT6A 7/4885KAT6B 16/4885 |
| US-20260027087-A1 | DOSING REGIMENS COMPRISING A KAT6 INHIBITOR FOR THE TREATMENT OF CANCER | KAT6A, KAT6B, KAT2A | KAT7 9/4885KAT6A 1/4885KAT6B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.